Mar 11, 2021 7:41am EST Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil
Mar 03, 2021 8:00am EST Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
Mar 01, 2021 8:00am EST Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)
Mar 01, 2021 7:00am EST Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer
Feb 25, 2021 7:00am EST Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference
Feb 19, 2021 8:00am EST Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
Feb 17, 2021 7:47am EST Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data
Feb 10, 2021 7:00am EST Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol
